Brenus Pharma graduates from the Creative Destruction Lab’s 2023/2024 Global Cancer Stream, in partnership with North American Universities.
June 27 2024 - 3:51PM
Business Wire
A year ago, Brenus was selected to participate in CDL Cancer, a
global mentorship program for massively scalable, science-based and
innovative companies accelerating cancer treatment.
Thanks to its pioneering STC platform, dedicated to developing a
new generation of therapeutic cancer vaccines, Brenus stood out
during a scientific evaluation with Dr. John Bell (Principal Senior
Scientist at Ottawa Hospital Cancer Research Institute &
Professor of Medicine & Immunology at University of
Ottawa).
Brenus has graduated from the program along with 9 other
companies, successfully completing the 4 sessions that took place
from October 2023 to June 2024 across North America.
In this program, Brenus came to seek strategic, international
guidance for the development of its platform and their lead
candidate targeting colorectal cancer.
During each session, the objectives and updates presented were
challenged by the CDL community and mentors: successful
entrepreneurs, investors, corporate partners, KOLs, and more, all
coming from prestigious institutions (University of New York,
Oxford, Toronto, British Columbia). The support received was
instrumental in validating Brenus Pharma’s roadmap and accelerating
the achievement of strategic milestones in R&D (multi-omics and
AI), finance and partnerships.
“The CDL sessions, based on an interesting “creative
destruction” method, allowed us to leverage expertise across the
CDL community and anticipate the next key steps to bring our
innovation to patients with urgent unmet needs. This year has
already been rich in achievements for Brenus, and we will continue
to drive operational excellence to bring our company further. We
are proud to have up taken the CDL challenge and we thank our
mentors for their trust.” said Paul Bravetti, CEO of Brenus
Pharma.
About CDL Cancer
This unique CDL-Global stream brings together global leaders and
experts across the cancer care continuum to support technology
innovations that improve the cancer experience globally, from
prevention to diagnosis, treatment, and survivorship.
About the Creative Destruction Lab
The Creative Destruction Lab (CDL) is a program for massively
scalable, science-based companies. The nine-month program employs
an objectives-based mentoring process with the goal of maximizing
equity-value creation. The CDL is particularly suited to early
stage companies with links to university research labs. Launched in
2012 at the Rotman School of Management at the University of
Toronto, the program has now expanded with locations in Vancouver,
Calgary, Montreal, Halifax, and New York City.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240627958275/en/
Marion BRUN, contact@brenus-pharma.com